Controlled clinical trial of a new dosage form of metaproterenol.
In a double-blind, crossover study of single doses an inhalant solution of metaproterenol was compared with an 0.5% solution of isoproterenol and placebo in nine patients with bronchial asthma and 13 patients with chronic obstructive pulmonary disease. The solutions were administered by IPPB in 15-minute treatment sessions. The mean duration of effect of metaproterenol, in terms of FEV1, and the magnitude of the FEV1 response to metaproterenol exceeded the isoproterenol data to a statistically significant degree, as did global ratings of response. FEF 25-75% and airway resistance showed similar patterns of response. Adverse experiences were minimal after both drugs.
D000328:Adult; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007545:Isoproterenol / Q000009:adverse effects; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D009921:Metaproterenol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged
D009921:Metaproterenol; D007545:Isoproterenol